Gene Therapy MCO-010 Moves Toward FDA Approval to Restore Vision in Retinal Disease

MCO-010 is an optogenetic gene therapy designed to restore functional vision in patients with advanced retinal degenerative diseases, conditions that progressively destroy photoreceptor cells and currently have very limited treatment options. Nanoscope Therapeutics has now partnered with Catalent to scale manufacturing and prepare for commercial launch, marking a significant step from clinical development toward real-world availability.

The therapy works by delivering a gene that reprograms remaining retinal cells — cells that survive even as photoreceptors die — to become light-sensitive. This approach sidesteps the root cause of degeneration and instead creates a new pathway for light detection, potentially restoring meaningful vision even in late-stage disease.

Clinical results have been encouraging. Nanoscope reported positive outcomes from the RESTORE Phase 2b/3 trial in retinitis pigmentosa and promising data from the STARLIGHT Phase 2 trial in Stargardt disease, a rare inherited macular dystrophy. A rolling FDA submission is already underway, and a Phase 3 registrational trial for Stargardt disease is planned for 2026. The therapy carries FDA Fast Track and Orphan Drug designations for both conditions, plus Regenerative Medicine Advanced Therapy designation for Stargardt, all of which accelerate its regulatory pathway.

Beyond these two indications, Nanoscope plans to expand MCO-010 into geographic atrophy — an advanced form of age-related macular degeneration affecting millions of older adults — with a Phase 2 program expected in 2026. Leber congenital amaurosis is also in the pipeline as an IND-ready program.

For longevity-focused readers, vision preservation is a critical but often overlooked component of healthspan. Loss of sight is strongly associated with cognitive decline, social isolation, and reduced physical activity in older adults. A therapy capable of restoring vision in degenerative retinal disease could meaningfully extend functional independence and quality of life.